Company profile

Vivoryon Therapeutics AG (formerly Probiodrug) specializes in the research and development of therapeutic products for the treatment of Alzheimer disease. At the end of 2018, the group has a portfolio of 2 products in clinical development phase (PBD-C06 and PQ912) and a product in the preclinical development phase.

Source: Cofisem - Last Update: 01 Apr 2020
Key Executives
Chairman of the Management Board Ulrich Dauer
Member of the Management Board Michael Schaeffer
Investor Relations Director Ulrich Dauer
Source: Cofisem - Last Update: 26 Sep 2019
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales
Income from ordinary activities
Operating income -7,715 -7,698 -9,961 -13,777 -13,393
Cost (net) of financial indebtedness -114 -112
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -7,823 -7,737 -8,009 -13,891 -13,505
Net income (Group share) -7,823 -7,737 -8,009 -13,891 -13,505
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 01 Apr 2020
Shareholder information
MorphoSys AG 13.40 %
T&W Holding A/S 9.50 %
Den Danske Forskningsfond 9.50 %
Claus Christiansen 9.50 %
Lupus alpha Investment S.A 6.90 %
Mackenzie Financial Corporation 5.20 %
IBG Group 4.50 %
Life Science Partners 3.20 %
Source: Cofisem - Last Update: 13 Mar 2020

Financial analysis

Equity research report, in partnership with Morningstar

View Report

Address

Vivoryon Therapeutics AG

Weinbergweg 22
DE-06120 Halle, Sachsen-Anhalt
Germany
Phone number: +49 345 555 9900
Source: Cofisem - Last Update: 01 Apr 2020

Contact

Ulrich Dauer
Source: Vivoryon Therapeutics AG - Last Update: 01 Apr 2020